Enlivex Therapeutics Ltd
NASDAQ:ENLV
Intrinsic Value
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. [ Read More ]
The intrinsic value of one
ENLV
stock under the Base Case scenario is
1.47
USD.
Compared to the current market price of 1.27 USD,
Enlivex Therapeutics Ltd
is
Undervalued by 14%.
Enlivex Therapeutics Ltd's market capitalization is 23.6m USD.
ENLV stock price is 1.27 USD.
ENLV stock price (1.27 USD) is 14% less than its Intrinsic Value (1.47 USD).
ENLV. Open Relative Valuation
ENLV has upside potential of 462% compared to the average analyst price target.
Open Wall St Estimates
ENLV has negative Free Cash Flow for the last twelve months.
ENLV has negative Operating Income for the last twelve months.
ENLV has negative Net Income for the last twelve months.
ENLV's ROE (Return on Equity) has significantly decreased in the last 3 years from -23% to -67%, and is approaching profitability.
ENLV's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -269% to -208%, and is approaching profitability.
ENLV's ROE (Return on Equity) for the past 12 months is negative and is equal to -67%.
ENLV's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -208%.
ENLV has negative three-year average ROE (Return on Equity): -39%. The company is not efficient at transforming stockholders' equity into net income.
ENLV has negative three-year average ROIC (Return on Invested Capital): -229%. The company is not efficient at using invested capital to generate operating income.
ENLV's short-term assets (34m USD) exceed its short-term liabilties (6m USD).
ENLV's long-term assets (37m USD) exceed its long-term liabilties (7m USD).
ENLV's D/E (Debt to Equity) is very low and is equal to 0.
ENLV's Altman Z-Score is very low and is equal to -2.04.
Valuation Backtest
Enlivex Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling
ENLV
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Enlivex Therapeutics Ltd
Balance Sheet Decomposition
Enlivex Therapeutics Ltd
| Current Assets | 33.8m |
| Cash & Short-Term Investments | 27.3m |
| Other Current Assets | 6.4m |
| Non-Current Assets | 3.1m |
| PP&E | 1.5m |
| Other Non-Current Assets | 1.5m |
| Current Liabilities | 6.1m |
| Accounts Payable | 827k |
| Accrued Liabilities | 4m |
| Other Current Liabilities | 1.2m |
| Non-Current Liabilities | 686k |
| Other Non-Current Liabilities | 686k |
Earnings Waterfall
Enlivex Therapeutics Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-25.2m
USD
|
|
Operating Income
|
-25.2m
USD
|
|
Other Expenses
|
-3.9m
USD
|
|
Net Income
|
-29.1m
USD
|
Free Cash Flow Analysis
Enlivex Therapeutics Ltd
What is Free Cash Flow?
ENLV Profitability Score
Profitability Due Diligence
Enlivex Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Enlivex Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ENLV Solvency Score
Solvency Due Diligence
Enlivex Therapeutics Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Enlivex Therapeutics Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENLV Price Targets Summary
Enlivex Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for
ENLV
is 7.14 USD
with a low forecast of 7.07 USD and a high forecast of 7.35 USD.
Ownership
ENLV Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ENLV Price
Enlivex Therapeutics Ltd
| Average Annual Return | -15.42% |
| Standard Deviation of Annual Returns | 23.29% |
| Max Drawdown | -97% |
| Market Capitalization | 23.6m USD |
| Shares Outstanding | 18 600 000 |
| Percentage of Shares Shorted | 1.36% |
Company Profile
Enlivex Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Contact
IPO
Employees
Officers
The intrinsic value of one
ENLV
stock under the Base Case scenario is
1.47
USD.
Compared to the current market price of 1.27 USD,
Enlivex Therapeutics Ltd
is
Undervalued by 14%.
You don't have any saved screeners yet
